A model three-dimensional culture system for mammalian dopaminergic precursor cells: application for functional intracerebral transplantation.
Grafts of fetal neural tissue, rich in dopamine (DA) neurons, have previously been shown to improve the symptoms of parkinsonism, both in humans and in animal models. In order to circumvent some of the problems associated with cell transplant therapy, such as the limited availability of transplant tissue, we have established a reaggregate (three-dimensional) tissue culture system that can be used to proliferate normal mammalian neuronal precursors. We demonstrate the in vitro growth of DA-neuronal precursors derived from embryonic porcine ventral mesencephalon, Carnegie stages 15-18. Cultures of DA-neuronal precursors were maintained in F12 medium supplemented with Chang C Supplement for 5 days and switched to serum-free N2 medium for an additional 10 days. Cultures labeled with tritiated thymidine on Days 5-7 in vitro revealed that 43.5% of the DA neurons had incorporated the label, indicative of cell division. Histological examination of the cultured cells demonstrated rosette-like structures, similar to developing neuroepithelium in vivo. Neuronal maturation in vitro was stimulated by dibutyryl cyclic AMP (dbcAMP). Exposure to 5 mM dbcAMP for 7 days stimulated tyrosine hydroxylase (TH), neuron-specific enolase, and 200-kDa neurofilament accumulation three- to sixfold above control levels. After 15 days in vitro, cultured cells reversed amphetamine-induced rotation when grafted into the striata of hemiparkinsonian rats. Successful transplants of cultured neurons were dependent upon a minimum density of DA neurons within the graft (greater than 100 DA neurons/mm3 of graft volume). Data suggest that the percentage of TH neurons can be increased about threefold by culturing the aggregates in tyrosine-free medium, which selects for TH-positive cells. The ability to cultivate mammalian neuronal precursor cells in vitro may eventually make graft therapy a more practical approach to treatment of neurological diseases.
Spector
D H
DH
Department of Psychiatry and Behavioral Science, SUNY at Stony Brook 11794.
Boss
B D
BD
Strecker
R E
RE
D000818:Animals; D016380:Brain Tissue Transplantation / Q000502:physiology*; D003994:Bucladesine / Q000494:pharmacology; D002449:Cell Aggregation; D002454:Cell Differentiation; D002478:Cells, Cultured; D004298:Dopamine / Q000378:metabolism*; D004622:Embryo, Mammalian; D016332:Fetal Tissue Transplantation / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D008636:Mesencephalon / Q000166:cytology* / Q000502:physiology / Q000637:transplantation; D009474:Neurons / Q000166:cytology* / Q000502:physiology / Q000637:transplantation; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000628:therapy*; D013552:Swine; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*
D003994:Bucladesine; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine